Considering the suboptimal response to chemo-immunotherapy (CIT) regimens in high risk CLL patients (IGHV unmutated, del 17p/TP53) [42] together with the incidence of AIC in CLL, it is of interest to assess the role of small molecule inhibitors (i.e., idelalisib, venetoclax, and ibrutinib) in the context of CLL-related AIHA. The gene discussed is TP53; the disease is autoimmune hemolytic anemia.